We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04597359
Recruitment Status : Recruiting
First Posted : October 22, 2020
Last Update Posted : May 25, 2023
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.

Condition or disease Intervention/treatment Phase
Prostate Carcinoma Drug: Placebo Administration Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Sinecatechins Phase 2

Show Show detailed description
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Actual Study Start Date : May 20, 2021
Estimated Primary Completion Date : December 31, 2032
Estimated Study Completion Date : December 31, 2032

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A (green tea catechins)
Patients receive green tea catechins PO BID for up to 6 months in the absence of disease progression or unacceptable toxicity.
 Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies

Drug: Sinecatechins
Given PO
Other Names:
  • Camellia sinensis Leaf Catechins
  • Kunecatechins
  • Polyphenon E
  • Polyphenon E TM
  • Veregen
Placebo Comparator: Arm B (placebo)
Patients receive placebo PO BID for up to 6 months.
 Drug: Placebo Administration
Given PO

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment

Other: Questionnaire Administration
Ancillary studies


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in the highest percent Ki-67 expression [ Time Frame: Baseline to 6 months ]
    Measured in a core positive for tumor from baseline to highest percent (%) Ki-67 expression measured in a core positive for tumor in the end of study (EOS) biopsy. This change will be compared between green tea catechins (GTC) and placebo arms. The highest % Ki-67 expressions from baseline and EOS biopsies will be used to estimate the change. If the change is not normally distributed, non-parametric test such as Wilcoxon-rank sum test or two-sample normal score test will be used to compare the changes in percent Ki-67 levels between the GTC and placebo arms.


Secondary Outcome Measures :
  1. Apoptosis [ Time Frame: Up to 6 months ]
    Will be assessed by caspase in tumor tissue from EOS biopsy by treatment.

  2. Apoptosis ratio [ Time Frame: Up to 6 months ]
    Will be evaluated from EOS biopsy by treatment groups. Descriptive statistics with confidence intervals will be presented. For continuous measures, will use two-sample t-test or Wilcoxon rank sum test (if non-parametric test is more appropriate) to compare the measurements by treatment.

  3. Number of biopsy cores positive for cancer at end of study [ Time Frame: At 6 months ]
    Descriptive statistics with confidence intervals will be presented. For binary measures, will use Fisher's test.

  4. Percent of any biopsy tissue core positive for cancer at end of study [ Time Frame: At 6 months ]
    Descriptive statistics with confidence intervals will be presented. For continuous measures, will use two-sample t-test or Wilcoxon rank sum test (if non-parametric test is more appropriate) to compare the measurements by treatment.

  5. Percent Ki-67 [ Time Frame: Up to 6 months ]
    Descriptive statistics with confidence intervals will be presented. For continuous measures, will use two-sample t-test or Wilcoxon rank sum test (if non-parametric test is more appropriate) to compare the measurements by treatment.

  6. Gleason sum at end of study [ Time Frame: At 6 months ]
    Descriptive statistics with confidence intervals will be presented. For binary measures, will use Fisher's test.

  7. Change in serum prostate-specific antigen (PSA) [ Time Frame: Baseline up to 6 months ]
    Will use three mixed models (for PSA, PSA doubling time, and PSA density). For the first two, will log the PSA value. For PSA, will have intercepts and slopes for each patient, an unstructured covariance model, and 2 terms for the intercept and slope associated with the treatment group. For the PSA doubling time, will center the baseline values at 1, and estimate the slopes for each patient (from which the doubling time can be derived), along with a net slope effect for the treatment group. The mixed model for PSA density will be analogous to the one for PSA.

  8. Incidence of adverse events [ Time Frame: Up to 12 months ]
    Will be assessed by Common Toxicity Criteria version 5.0, complete blood count, comprehensive metabolic panel, and liver function toxicities by treatment. All toxicity data will be summarized by category and grade in a standard fashion. Proportions experiencing the most common types of toxicity in this trial will be estimated and 95% confidence intervals calculated. Adverse event rates (such as worst grade 3 or higher) by arm will be estimated and compared.

  9. Change in geometric mean of percent Ki-67 [ Time Frame: Baseline up to 6 months ]
    Descriptive statistics with confidence intervals will be presented. For binary measures, will use Fisher's test.


Other Outcome Measures:
  1. Compliance to study drug (standard pill counts) [ Time Frame: Up to 6 months ]
    Compliance to study drug will be evaluated by standard pill counts. Will evaluate percentage compliance to study agent in the study arms using pill counts.

  2. Compliance to study drug (diet records) [ Time Frame: Up to 6 months ]
    Compliance to study drug will be evaluated by diet records.

  3. Compliance to study drug (plasma concentrations of GTC) [ Time Frame: Up to 6 months ]
    Compliance to study drug will be evaluated by plasma concentrations of GTC (epigallocatechin gallate [EGCG]). For plasma, will assess the change from baseline to end of treatment for GTC (EGCG) to estimate compliance and bioavailability.

  4. Epigallocatechin gallate (EGCG) concentrations [ Time Frame: Up to 6 months ]
    Will correlate EGCG concentrations with prostate specific antigen density (PSAD) and prostate specific antigen doubling time (PSADT), using descriptive analysis with scatter plots and regression analysis, and adjusting intervention and known predictors including the stratification factors in multivariable analysis. Will transform to the square root or logarithmic transformation of the data to improve normality of the distributions (determined as the transformation (including untransformed) with the lowest Anderson-Darling normality score).

  5. Changes in lower urinary tract symptoms (LUTS) [ Time Frame: Baseline up to 6 months ]
    Lower urinary tract symptoms (LUTS) will be assessed using the American Urological Association Symptom Score for the evaluation, LUTS Symptom Scale. The highest score on the scale is 5, "almost always" and the lowest score on the scale is 0, "not at all".

  6. Changes in lower urinary tract symptoms [ Time Frame: Baseline up to 6 months ]
    Will assess change in EGCG from baseline to EOS, adherence to GTC, and bioavailability of GTC from baseline to EOS by treatment.

  7. Changes in quality of life (QOL) [ Time Frame: Baseline up to 6 months ]
    Quality of life will be assessed using the Functional Assessment of Cancer Therapy (FACT)-Prostate.

  8. Changes in quality of life (QOL) [ Time Frame: Baseline up to 6 months ]
    Will assess change in EGCG from baseline to EOS, adherence to GTC, and bioavailability of GTC from baseline to EOS by treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • INCLUSION CRITERIA FOR PREREGISTRATION (STEP 0: SCREENING)
  • Patient must have biopsy-proven (consisting of >= 12 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core in the most recent biopsy using initial transrectal ultrasound (TRUS) biopsy or TRUS biopsy followed by multiparametric magnetic resonance imaging (mpMRI) of the prostate and a confirmatory targeted biopsy
  • Patient must be on active surveillance (very low, low and favorable intermediate risk as defined by the National Comprehensive Cancer Network [NCCN])
  • Patient must be scheduled for a follow up prostate biopsy 6 months after the initiation of treatment on this study
  • Patient must have a serum PSA < 10 ng/mL or prostate specific antigen density (PSAD) < 0.15 ng/mL/ g obtained within 30 days of registration
  • Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Patient must be willing to abstain from consumption of any supplements containing green tea catechins
  • Patient must be willing to restrict tea consumption to less than three (3) servings of hot tea or three (3) servings of iced tea per week (serving size of 8 oz)
  • Patient must be willing to discontinue current vitamin/mineral supplement use and use one provided by study
  • Patient must be willing to take study agent or placebo at the dose specified with meals
  • Patient must have the ability to understand and the willingness to sign a written informed consent document
  • Absolute neutrophil count >= 1,200/mm^3 (>= 1.2 k/uL) (obtained within 30 days prior to registration)
  • Platelets >= 75,000/mm^3 (>= 75 k/uL) (obtained within 30 days prior to registration)
  • Total bilirubin =< 1.2 mg/dL (or =< 3.0 mg/dL for patients with Gilbert's syndrome) (obtained within 30 days prior to registration)
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x upper limit of normal (ULN) (obtained within 30 days prior to registration)
  • Serum creatinine =< 1.5 x ULN (obtained within 30 days prior to registration)
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • Sexually active males must use an accepted and effective method of double barrier contraception (vasectomy must be combined with a physical barrier method) or abstain from sexual intercourse for the duration of their participation in the study

  • Patients must have archived formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen available for Gleason score confirmation and % Ki-67 expression (5% or more) in tumor tissue for eligibility and stratification. Tumor tissue can be submitted any time during screening

    • Tumor tissue specimen has been collected and is ready to ship to H. Lee Moffitt Cancer Center & Research Institute

      • H. Lee Moffitt Cancer Center & Research Institute will perform Gleason score confirmation and % Ki-67 expression (5% or more) in tumor tissue and notify the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Operations Office and submitting institution within 3-4 business days of receipt of the tumor tissue specimen
  • INCLUSION CRITERIA FOR RANDOMIZATION (STEP 1)
  • Patient must meet all Step 0 eligibility criteria at the time of their registration to Step 1
  • Patient must have Gleason score (3+3) or predominant Gleason pattern 3 (3+4), =< 33% of biopsy cores, and =< 50% involvement of any biopsy core
  • Patient must have % Ki-67 expression of 5% or more in tumor tissue

Exclusion Criteria:

  • EXCLUSION CRITERIA FOR PREREGISTRATION (STEP 0: SCREENING)
  • Patient must not have had prior treatment for prostate cancer, including focal therapy, with surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen deprivation therapy
  • Patient must not have a history of renal or hepatic disease, including history of hepatitis B and C
  • Patient must not have prostate cancer with distant metastases
  • Patient must not have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patient must not receive any other investigational agents while on this study
  • Patient must not have a history of allergic reactions attributed to tea or other compounds of similar chemical or biologic composition to green tea extracts
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04597359


Locations
Show Show 307 study locations
Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Nagi B Kumar ECOG-ACRIN Cancer Research Group
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT04597359    
Other Study ID Numbers: EA8184
NCI-2020-07173 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
EA8184 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
ECOG-ACRIN-EA8184 ( Other Identifier: DCP )
EA8184 ( Other Identifier: CTEP )
UG1CA189828 ( U.S. NIH Grant/Contract )
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: May 25, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases